1. a) Total bacterial load at baseline (V0) and after 12 months of therapy (V4) in sputum samples of patients treated with salmeterol/fluticasone propionate (SALM/FP) with baseline blood eosinophil counts ≥2% or <2% of total leukocytes. b) Total bacterial load...
a) Total bacterial load at baseline (V0) and after 12 months of therapy (V4) in sputum samples of patients treated with salmeterol/fluticasone propionate (SALM/FP) with baseline blood eosinophil counts ≥2% or <2% of total leukocytes. b) Total bacterial load at baseline (V0) and after 12 months of therapy (V4) in sputum samples of patients treated with SALM/FP with baseline sputum eosinophil counts ≥2% or <2% of total inflammatory cells. c) Total bacterial load at baseline (V0) and after 12 months of therapy (V4) in sputum samples of patients treated with SALM/FP with or without recurrent sputum eosinophilia ≥2% in at least 50% of available samples obtained at scheduled visits (at least 2 visits) during the 1-year study. d) Correlation between blood eosinophils and bacterial load at baseline. e) Sputum microbial quantification of the SALM/FP treated patients with baseline blood eosinophil levels <2% or ≥2%. *: p<0.05.
Marco Contoli et al. Eur Respir J 2017;50:
©2017 by European Respiratory Society